Cargando…
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
Inhibition of HER2 in HER2-amplified breast cancer has been remarkably successful clinically, as demonstrated by the efficacy of HER-kinase inhibitors and HER2-antibody treatments. Whilst resistance to HER2 inhibition is common in the metastatic setting, the specific programs downstream of HER2 driv...
Autores principales: | Smith, Alison E., Ferraro, Emanuela, Safonov, Anton, Morales, Cristina Bernado, Lahuerta, Enrique J. Arenas, Li, Qing, Kulick, Amanda, Ross, Dara, Solit, David B., de Stanchina, Elisa, Reis-Filho, Jorge, Rosen, Neal, Arribas, Joaquín, Razavi, Pedram, Chandarlapaty, Sarat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602441/ https://www.ncbi.nlm.nih.gov/pubmed/34795269 http://dx.doi.org/10.1038/s41467-021-27093-y |
Ejemplares similares
-
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
por: Chandarlapaty, Sarat, et al.
Publicado: (2009) -
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017) -
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023) -
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022) -
Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
por: She, Qing-Bai, et al.
Publicado: (2008)